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The cytotoxic action of the chloroethylnitrosoureas and related
methylating agents (O6-alkylating agents) has long been exploited
in the treatment of cancer. Their cytotoxicity, mutagenicity,
carcinogenicity and clastogenicity has been shown to be due in
large part to their ability to alkylate DNA and in particular to form
O6-alkylguanine (O6-alkG). Cells, both normal and neoplastic,
possess the ability to repair this adduct via a single step reac-
tioninvolving O6-alkylguanine-DNA alkyltransferase (ATase)
(Yarosh, 1985; Pegg and Dolan, 1987; Margison and O’Connor,
1990; Pegg, 1990; Pegg and Byers, 1992). ATase catalyses the
transfer of the alkyl group from DNA to a cysteine acceptor site
within the protein, resulting in the auto-inactivation of the ATase.
Restoration of activity therefore requires de novo protein synthesis
and so the capacity of cells to repair O6-alkG is transiently limited
by the number of ATase molecules present. Consequently, the
sensitivity of a given normal or neoplastic cell to the biological
effects of O6-alkG strongly correlates with ATase activity
(Brennand and Margison, 1986; Jelinek et al, 1988; Kaina et al,
1991; von Hofe et al, 1992; Brent et al, 1993; Dumenco et al,
1993; Nakatsuru et al, 1993; Jelínek et al, 1996; Moritz et al,
1995). For this reason the depletion of ATase in tumours has
become a therapeutic target in order to sensitize tumours to O6-
alkylating agent treatment (Dolan et al, 1985; Gerson et al, 1988;
Mitchell et al, 1992; Wedge and Newlands, 1992b; Margison et al,
1996; Kurpad et al, 1997).
One agent that can be used to deplete cellular ATase levels is O6-
benzylguanine (BG) (Bronstein et al, 1992; Dolan et al, 1994;
Dolan and Pegg, 1997). Inactivation of ATase with BG has been
demonstrated to be irreversible, indicating that it acts as an
alternative substrate for the protein (Dolan et al, 1990; Pegg et al,
1993) and can potentiate the effects of anti-tumour agents against
otherwise resistant cells and tumours (Mitchell et al, 1992; Baer 
et al, 1993; Kurpad et al, 1997). The combination of BG and 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU) is currently undergoing
phase I clinical trials (Pegg et al, 1993; Hickson et al, 1996).
The effectiveness of the clinically used O6-alkylating agents is
limited by their relatively unselective and frequently dose-limiting
toxicity to normal tissues. In response to this problem a number of
molecular combinations of 5-fluorouracil (5FU) and chloroethyl-
nitrosourea (CNU) have been developed (McElhinney et al,
1989a, 1989b) with the aim of producing agents with good activity
against tumours but which may be less toxic to normal tissue. It
was anticipated that the molecular combinations would result in a
more gradual release in vivo of an active component, in a manner
not possible when the two free components are administered sepa-
rately. Studies to date on a limited number of these compounds
have suggested that 5FU release per se does not seem to account
for their anti-tumour activity, but instead indicates that the alkyl-
ating components of these drugs are highly effective in this confor-
mation. Three of these compounds (Figure 1) were selected for
further study on the basis of previously described preliminary anti-
tumour studies: B.3995 (McElhinney et al, 1989a), in which the
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SummaryPrevious studies have demonstrated that novel molecular combinations of 5-fluorouracil (5FU) and 2-chloroethyl-1-nitrosourea
(CNU) have good preclinical activity and may exert less myelotoxicity than the clinically used nitrosoureas such as 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU). This study examined the effect of O6-alkylguanine-DNA-alkyltransferase (ATase) depletion by the pseudosubstrate O6-
benzylguanine (BG) on the anti-tumour activity and normal tissue toxicity in mice of three such molecular combinations, in comparison with
BCNU. When used as single agents at their maximum tolerated dose, all three novel compounds produced a significant growth retardation of
BCNU-resistant murine colon and human breast xenografts. This in vivo anti-tumour effect was potentiated by BG, but was accompanied by
severe myelotoxicity as judged by spleen colony forming assays. However, while tumour resistance to BCNU was overcome using BG, this
was at the expense of enhanced bone marrow, gut and liver toxicity. Therefore, although this ATase-depletion approach resulted in improved
anti-tumour activity for all three 5-FU:CNU molecular combinations, the potentiated toxicities in already dose-limiting tissues indicate that
these types of agents offer no therapeutic advantage over BCNU when they are used together with BG.
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linear pseudo-sugar fragment linking the CNU and the 5FU by the
normal N1 has been greatly simplified, the closely-related B.3996
(McElhinney et al, 1989b), containing sulphur in place of the
normal sugar oxygen and an N3 link to the pyrimidine ring and
B.4152 (Loadman et al, 1996) which retains all four carbon atoms
of the furanose skeleton, although lacking the usual sugar
hydroxyl groups. Previous studies have shown B.4152 to be rela-
tively marrow-sparing in a mouse in vivo model (Loadman et al,
1996).
Here we report the results of a study designed to determine the
capacity of BG to potentiate the anti-tumour activity of B.3995,
B.3996 and B.4152, in comparison to BCNU, and to investigate
the extent to which these molecular combinations are sparing to
normal tissues, particularly the bone marrow.
MATERIALS AND METHODS
Animals
Pure strain NMRI mice from an inbred colony were purchased
from B&K Universal Ltd, Hull, UK. NCR/Nu mice were obtained
from the National Cancer Institute, Frederick, Maryland, USA.
They were fed with a pellet diet (CRM, Special Diets Services,
Witham, Essex, UK) and water ad libitum. Nude mice were
housed in isolation cabinets. All mice had reached a minimum age
of 8 weeks before use. Animal experiments were conducted in
compliance with an approved project licence (Home Office,
London, UK).
Test compounds
BCNU was obtained from Bristol-Myers Pharmaceuticals (UK).
BG and the molecular combinations B.3995, B.3996 and B.4152
were synthesized by Dr JE McCormick, Trinity College, Dublin
(McCoss et al, 1985; McElhinney et al, 1989a, 1989b; McMurray
et al, 1994; Loadman et al, 1996). BG was solubilized in
Cremophor/saline (1/10 v/v), BCNU in ethanol/saline (1/10) and
B-series compounds in dimethylsulphoxide (DMSO)/arachis oil
(1/10 v/v). All treatments were by single intraperitoneal (i.p.)
injection.
Tumour systems
Fragments (~ 1–2 mm3) of murine colon adenocarcinoma MAC-
26 were transplanted into the flank of groups of male NMRI mice
by means of a trocar (Loadman et al, 1996). The MAC-26 tumour
was selected because of its general resistance to nitrosoureas. 
MT-1 human breast cancer xenografts (Naundorf et al, 1992) 
were similarly transplanted into female NCR nude mice.
ATase activity
Tumour, liver, bone marrow and small intestine samples were
obtained from NMRI and NCR-Nu mice after either 15 (NMRI
only) or 120 min (NMRI and NCR-Nu) post-treatment with 
60 mg kg–1 BG or after being treated with the solvent vehicle only.
Marrow samples for NCR-Nu were pooled before ATase activity
determination because of low protein levels. Prior to assay, the
biopsies were frozen in liquid nitrogen and stored at – 80°C. The
ATase assay was performed as described previously (Lee et al,
1991, 1992), and is based upon the transfer of [3H]methyl groups
from substrate DNA to ATase protein present in tissue extracts.
Briefly, tissue extracts were prepared at 4°C by sonication in
buffer I (50 mM Tris-HCl, 3 mM DL-dithiothreitol and 2 mM
EDTA, pH 8.3) containing leupeptin (0.5 ml ml–1) with 10 ml
phenylmethylsulphonyl fluoride (87 mg ml–1) added after sonica-
tion. For the assay, aliquots of the extract were incubated with [3H]
substrate DNA at 37°C for 30 min, after which the DNA was
hydrolysed in 1 M perchloric acid at 75°C for 50 min. The samples
were then centrifuged and washed in 1 M perchloric acid before
resuspension in 10 mM sodium hydroxide and aqueous scintilla-
tion fluid (Ecoscint A; National Diagnostics). Protein was esti-
mated using the Bradford method (Bradford, 1976) with bovine
serum albumin used as the standard. ATase activity was expressed
as femtomoles (fmol) of methyl groups transferred to protein per
milligram of total protein in the extract.
Chemotherapy
Tumour-bearing animals were allocated into groups (minimum 8)
and treatment commenced when tumours were large enough to be
accurately measured by calipers (~ 4 ´ 4 mm). Anti-tumour effects
were assessed by twice-weekly two-dimensional caliper measure-
ments of the tumours and their volumes were calculated from the
formula a2 ´ b/2, where a is the smaller diameter and b the larger
(Geran et al, 1972). Growth curves were constructed and compar-
isons made between treated and control groups: solvent control
groups were also included. Efficacy was determined on the basis
of the difference in time taken for control and treated tumours to
double in volume.
Normal tissue toxicity
Gastrointestinal and hepatic toxicity was assessed in non-tumour
bearing BALB/c mice following treatment with BCNU alone 
(20 mg kg–1) or in combination with BG (60 mg kg–1 2 h prior to
BCNU). After 3 days the animals were killed by cervical disloca-
tion and the tissues of interest removed. These were immediately
fixed in Bouin’s reagent for 24 h, dehydrated and embedded in
paraffin wax for sectioning before staining with haematoxylin and
eosin (H & E) and examination by light microscopy.
Acute bone marrow toxicity was assessed using a modified
version of the spleen colony forming assay of Till and McCulloch
(1961), similar to that used elsewhere (Patchen, 1995; Lord et al,
1996). Using a single time-point of 24 h post-treatment (Siemann
and Beyers, 1993; Down et al, 1994; Siemann, 1996), marrow
cells were obtained from both femora of pairs of treated or control
mice and suspended in RPMI tissue culture medium. Cell suspen-
sions were diluted so that a 0.2 ml aliquot contained an appropriate
number of cells for each experimental group. Cell inocula of 5.0 ´
104 to 7.5 ´ 105 were initially obtained from marrows of control
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Figure 1 Molecular structures of the molecular combinations of CNU and
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mice in order to investigate the relationship between the number of
spleen colonies formed and the number of marrow cells inoculated
intravenously (i.v.) via the tail vein. On the basis of these initial
experiments cell inocula of 1.0 to 2.5 ´ 105 were used for further
studies. Cells from control or treated mice were injected i.v. into
recipient mice which had been exposed to a marrow ablative dose
of X-irradiation (11.7 Gy) from a Newton Victor Superficial
Therapy Unit (GX 10). Groups of six mice were used for each
experimental point. After 8 days the mice were sacrificed, the
spleens removed and fixed in Bouin’s reagent and the nodules on
the surface were counted. The surviving fraction was determined
by comparison of the mean number of colonies observed with the
number of colonies expected for a given cell inoculum of marrow
cells from untreated mice.
RESULTS
ATase activity in NMRI mice and MAC-26 tumours
The mean ATase activity in the livers of NMRI mice was 
121  ± 26 fmol mg–1 total cellular protein. Fifteen minutes after
treatment with 60 mg kg–1 BG, this activity had rapidly decreased
to below 2 fmol mg–1 (i.e. less than 2% of the pretreatment levels),
the limit of detection of this assay and substrate: 2 h after treatment
the activity remained depressed at < 2 fmol mg–1. The NMRI bone
marrow had a control activity of 61 fmol mg–1 which, after 2 h, had
fallen to 17 fmol mg–1 (28% of the pretreatment activity). The
MAC-26 tumour had a mean control ATase activity of 
84  ± 7 fmol mg–1. Fifteen minutes after treatment with BG, the
activity had fallen to 2 ± 0.2 fmol mg–1 (2.5% of the pretreatment
levels) and again, after 2 h activity was found to be below the level
of detection of the assay.
ATase activity in NCR-Nu mice and MT-1 tumours
Control NCR-Nu liver had a mean ATase activity of 
55  ± 4 fmol mg–1. Two hours after treatment with BG, this was
reduced to < 2 fmol mg–1 (i.e. to below 3.6% of the pretreatment
level). The NCR-Nu marrow had a control activity of 30 fmol mg–1
which, similarly to the NMRI marrow, was reduced to only 
9 fmol mg–1 (30% of the control ATase activity) 2 h after treatment
with 60 mg kg–1 BG. The MT-1 tumour had a mean activity of 
262 ± 7 fmol mg–1 which, 2 h after 60 mg kg–1 BG, had been
reduced to 4 ± 2 fmol mg–1 (1.5% of the control).
When the assay was carried out on intestinal tissue, activity was
not detected in any of the samples (treated or control), probably
due to excess protease, released during the extraction procedure,
reducing the ATase activity to below detectable levels.
Anti-tumour studies
Activity against MAC-26 tumours
The results of anti-tumour studies using the experimental agents
either alone or in combination with BG on MAC-26 xenografts are
presented in Table 1. Growth delays analysed by a Mann-Whitney
U-Test indicated significant (P < 0.05) anti-tumour activity for
B.3995, B.3996 and B.4152 at their maximum tolerated doses
(MTD) compared with BCNU alone which was not effective
against this tumour even at the highest dose used. Combination
with BG increased the normal tissue toxicity of each compound,
requiring a reduction in their dose levels to ensure that equi-toxic
drug levels were administered. In each case pretreatment with BG
resulted in significant enhancement of the anti-tumour activities of
the B-series compounds: this was particularly evident for B.3996
where effects were seen with a dose of only 15 mg kg–1 combined
with BG. Furthermore, even the lowest dose of BCNU adminis-
tered was able to effect significant tumour growth delay if
preceded by treatment with 60 mg kg–1 BG. Statistical analysis of
the tumour growth delay of the four different anti-tumour agents
demonstrates that there is no significant difference (P > 0.05)
between BCNU and the three B-series compounds when used in
combination with BG.
Activity against MT-1 tumours
Anti-tumour studies with the human breast MT-1 xenograft model
were not completed due to the excessive normal tissue toxicity
observed when the treatments were combined with BG. Two dose
levels of BCNU (20 and 10 mg kg–1) were examined in combina-
tion with BG, neither of which when used alone were found to
produce a significant growth delay. In combination, both doses
produced anti-tumour effects but excessive weight loss resulted in
the experiments being terminated to avoid suffering. However, the
available data suggested that BG potentiated the anti-tumour
activity of BCNU against MT-1, given that the relative tumour
volumes of the BCNU/BG treated animals were 34% (10 mg kg–1)
and 50% (20 mg kg–1) less than both the control or BCNU-only
treated groups.
Normal tissue toxicity
Bone marrow
The toxic effect of BCNU, either alone or in combination with BG,
on the bone marrow spleen colony forming cells is presented in
Table 2. Treatment with BG alone had no obvious effect on spleen
colony formation, whereas BCNU had severe effects at doses of 40
and 20 mg kg–1, reducing CFU-S survival to 3% and 21% respec-
tively. A more modest toxicity was produced by a single dose 
of 10 mg kg–1, with 77% of CFU-S surviving BCNU exposure.
Table 1 Anti-tumour activity against MAC-26 murine colon
adenocarcinoma.
Treatment Dose (mg kg–1) Growth delay  Statistical 
(days) significance
BG 60 0 –
BCNU 40 0.20 NS
BCNU 20 0.05 NS
BG/BCNU 60/20 2.45 P < 0.05
B.3995 50* 3.65 P < 0.05
B.3995 20 0.45 NS
BG/B.3995 60/20 5.15 P < 0.01
B.3996 100* 9.15 P < 0.01
B.3996 10 0.32 NS
B.3996 15 1.12 NS
BG/B.3996 60/10 1.60 P < 0.05
BG/B.3996 60/15 10.77 P < 0.01
B.4152 70* 2.0 P < 0.05
B.4152 20 –0.9 NS
BG/B.4152 60/20 11.75 P < 0.01
*Signifies maximum tolerated doses of single agents. In each combination
experiment cytotoxic therapy was administered as a single i.p. dose 2 h after
BG.Anti-tumour effect of BG with BCNU or three novel nitrosoureas 1335
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However, the toxicity of this dose was dramatically potentiated by
BG, with no discernible colonies being present in animals exposed
to the combination treatment.
Data from similar studies with B.3995, B.3996 and B.4152 are
recorded in Table 3. In each case the molecular combinations
caused a reduction in CFU-S at maximum tolerated dose and
reduction in dose resulted in a corresponding reduction in bone
marrow toxicity. Combination with BG at doses optimized for an
anti-tumour effect resulted in very severe toxicity to the bone
marrow with no CFU-S detected under these conditions.
Liver
Liver toxicity was observed in animals treated with BG followed 
2 h later by 20 mg kg–1 BCNU, and consisted of numerous foci of
intracellular fatty globulation (Figure 2A and B). Animals treated
with either compound alone did not exhibit any observable
toxicity.
Gastrointestinal tract
The combination of BG with 20 mg kg–1 BCNU produced a clear
and dramatic change in the appearance of the intestine. The villi
were lost from the small intestine with only a small amount of
cellular debris remaining in the lumen (Figure 2C and D).
Intestinal toxicity was not observed in the animals treated with
BCNU or BG alone, with the villi and associated tissue appearing
normal in morphology.
Body weight loss occurred when BG was combined with either
BCNU or any of the B-series. Weight loss was most marked in the
NCR/Nu and BALB/c mice where experiments had to be ended 4
days post-treatment due to excessive weight loss [NCR/Nu mean
loss 25.7% (± 3.28) 4 days after 60 mg kg–1 BG and 20 mg kg–1
BCNU]. A reduction in the dose of BCNU to 10 mg kg–1 resulted
in reduced, but still excessive, weight loss (mean 16.16%, ± 0.04)
after 3 days.
Weight loss was also observed in the NMRI mice, but to a lesser
extent, reaching a nadir 7 days post-treatment with 60 mg kg–1 BG
and 20 mg kg–1 BCNU (mean loss 6.43%, ± 2.79), increasing
thereafter. When combined with BG, the B-series compounds
produced some weight loss in the NMRI mice, but similarly to
BCNU/BG, this was found to be 4–8% with a nadir of 7–8 days
post-treatment, increasing after this point.
DISCUSSION
The ATase inactivator BG has been widely reported to potentiate
the anti-tumour activity of various established O6-alkylating
agents such as BCNU, CCNU and temozolomide (Dolan et al,
1990; Mitchell et al, 1992; Chinnasamy et al, 1997; Kurpad et al,
1997). Here we report the effect of several novel nitrosoureas,
either alone or in combination with BG, on a murine colon adeno-
carcinoma (MAC-26) and a human breast carcinoma (MT-1).
Both tumour types express relatively high levels of ATase: the
mean activities determined for MAC-26 and MT-1 were 
84  ± 7 fmol mg–1 and 262 ± 7 fmol mg–1 respectively. These activ-
ities are similar to those found in other tumours such as human
glioma xenografts (Kurpad et al, 1997), testis and bladder tumour
cell lines (Walker et al, 1992) and human b-lymphoblastoid cell
lines (Bronstein et al, 1992).
Prior to the anti-tumour and normal cell toxicity studies, the
degree and kinetics of ATase depletion in the tissues to be analysed
was determined. BG rapidly depleted the ATase activity in normal
tissues of both mouse strains and also in both tumour xenografts.
The speed and degree of the depletion in ATase activity is similar
to that reported elsewhere for both normal (Dolan et al, 1990;
Chinnasamy et al, 1997) and tumour tissue (Mitchell et al, 1992;
Pegg at al, 1993), with a rapid and considerable depletion
observed over the initial 15 min after the dose of BG. The two
normal tissues examined responded slightly differently to the BG,
with the liver ATase activity being depleted to below detectable
levels, while the bone marrow maintained a higher ATase level
after BG, confirming the observations reported by Chinnasamy et
al (1997). The reasons for this tissue maintaining ATase activity
are unclear, but it could be that non-haematopoietic cells in the
marrow retain residual activity, or possibly differential penetration
of the inactivator into different areas of the bone marrow occurs.
The level of ATase activity observed in the xenografts was
apparently sufficient to protect against the anti-tumour effects of
various doses of BCNU. However, it was possible to produce a
significant growth delay in vivo against both tumour types, by
pretreatment with the ATase-depleting doses of BG.
In view of the extreme sensitivity of NCR/nu mice to BG and
treatment with BCNU, as evidenced by the excessive weight loss
experienced by the mice during this regimen, the 5FU:CNU mole-
cular combinations were evaluated in the syngeneic NMRI/MAC-
26 murine model. These molecular combinations were designed to
provide new agents offering effectiveness against previously prob-
lematical solid tumours. For all three investigational compounds,
Table 2 Influence of BG on the toxicity of BCNU to murine CFU-S
Treatment Dose (mg kg–1) Number of Number of Survival
colonies colonies fraction
observed* expected
BG 60 20.7 ± 1.5 24.9 0.83
BCNU 40 0.83 ± 0.75 28.5 0.03
BCNU 20 5.0 ± 2.1 23.4 0.21
BCNU 10 18.5 ± 3.4 24.1 0.77
BG/BCNU 60/10 0 27.4 0
*Mean ± 1 SD
Table 3 Influence of BG on the toxicity of B.3995, B.3996 and B.4152 to
murine CFU-S
Treatment Dose (mg kg–1) Number of Number of Survival
colonies colonies fraction
observed* expected
B.3995 50 5.5 ± 2.3 39.6 0.14
B.3995 25 13.5 ± 1.1 31.4 0.43
B.3995 20 12.0 ± 1.3 28.2 0.43
BG/B.3995 60/20 0 57.5 0
B.3996 100 2.8 ± 0.8 33.5 0.08
B.3996 50 6.8 ± 0.8 40.4 0.17
B.3996 25 18.2 ± 2.0 34.3 0.53
B.3996 15 11.3 ± 1.5 22.9 0.49
BG/B.3996 60/15 0 26.9 0
B.4152 100 10 ± 1.1 31.25 0.32
B.4152 50 12.2 ± 1.3 20 0.61
B.4152 25 16.3 ± 1.6 22.32 0.73
B.4152 20 20.8 ± 1.2 25.2 0.83
BG/B.4152 60/20 0 36.6 0
*Mean ± 1 SD1336 MC Bibby et al
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Figure 2 Normal tissue toxicity after 60 mg kg–1 BG and 20 mg kg–1 BCNU. (A) Normal liver. (B) Liver with fatty globulation. (C) Normal small intestine. (D) loss
of villi after treatment. H and E stained ´ 700
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when compared to BCNU, significant growth delays were evident
against MAC-26 tumours when the agents were used at their
MTD. This growth delay was very significantly potentiated by
pretreatment with BG: in particular, B.3996 and B.4152 were
found to be about 4 and 5 times better respectively at inducing
growth delay, if administered in combination with BG rather than
alone at their MTD.
One of the important aims in designing the novel combinations
was to attempt to reduce normal tissue toxicity, particularly
towards the bone marrow. It is important in this regard to note that
B.4152 as a single agent, while being significantly active against
refractory mouse adenocarcinoma tumour models has also been
shown to exert reduced myelotoxicity (Loadman et al, 1996). To
determine the acute haematological toxicity of the novel agents,
either alone or in combination with BG, the spleen colony forming
unit assay was used as with other published work (Bibby et al,
1988, 1993; Hendricks et al, 1993; Matthew et al, 1993, 1994;
Patchen, 1995; Loadman et al, 1996). In order to allow comparison
with a clinically relevant agent, BCNU was also included in this
study. In all cases, pretreatment with BG resulted in complete
ablation of the CFU-S compartment, and thus in this assay of acute
haematological toxicity, the novel nitrosoureas examined appear
to offer no significant therapeutic advantage over BCNU when
used in combination with BG. When used as single agents at their
MTD, however, B.4152 again appears to be significantly more
marrow-sparing than the two other B-series compounds, which in
turn appear more sparing than BCNU.
Interestingly, the dose of BG used did not entirely deplete the
ATase activity of bone marrow and approximately 30% activity
(17 fmol mg–1) remained at 2 h post-treatment, a situation similar
to that observed by Chinnasamy et al (1997). This level of activity
might be anticipated to confer some protection against nitrosourea
toxicity. However, the lack of any colonies in the CFU-S assay
suggest that the residual ATase activity observed in the marrow
after BG treatment may originate from non-haematopoietic cells.
In the same animals, a severe potentiation of toxicity was also
observed in both liver and intestine, as judged by histological
examination, following a BG/BCNU regimen. We have previously
reported that the testicular toxicity of nitrosoureas in mice is
elevated as a result of BG exposure (Thompson et al, 1996). Thus,
the widespread and non-tissue specific BG-mediated depletion of
ATase may prove to be problematic when this agent is used in a
clinical context.
What selectivity the novel 5FU:CNU molecular combinations
possess appears to be totally abolished when the repair capacity
for O6-alkG is depleted or, as in the case of bone marrow, reduced.
It seems more probable that these novel agents will be more useful
as single agents, given their reduced toxicity towards normal
tissues in this context. It is worthwhile to note that when compared
to BCNU, the B-series compounds were found to be significantly
more active when used as single agents and all produced reduced
acute haematological toxicity.
Other alkylating agents are currently being investigated in combi-
nation with BG to determine whether they offer any advantage over
BCNU. For example, the methylating agent temozolomide has
shown promising activity in phase I and II clinical trials (Newlands
et al, 1992; O’Reilly et al, 1993) against glioblastoma. Preclinical
work has shown that in combination with BG, it may offer a thera-
peutic advantage over BCNU (Wedge et al, 1996; Wedge and
Newlands, 1996), although dose and time of administration may be
critical as other reports show enhanced haemopoietic toxicity of
temozolomide/BG combinations (Fairbairn et al, 1995; Chinnasamy
et al, 1997).
If BG is to be widely useful clinically, it may be necessary to
attempt to select as targets for cytotoxic therapy those tumours
which more rapidly accumulate BG than normal tissues (Kurpad et
al, 1997) or to promote the selective uptake of BG into tumour
tissues by exploiting differences between normal tissues and the
relatively abnormal physiology and microenvironment of tumours.
Alternatively, it may be possible to protect haematopoietic cells in
vivo from the biological effects of O6-alkylating agents while
simultaneously allowing the sensitization of tumours to these
agents using BG (reviewed in Rafferty et al, 1996). Mutations in
the human ATase that lead to resistance to BG inactivation have
been reported (Crone and Pegg, 1993) and expression of these
cDNAs in cell lines has been shown to provide resistance to the
cytotoxic effects of combined BG and nitrosourea treatment
(Hickson et al, 1996; Loktionova and Pegg, 1996). Furthermore,
retroviral transduction of human primary haemopoietic progeni-
tors (CD34+) with cDNAs encoding BG resistant mutants of ATase
also resulted in increased resistance to BG with either BCNU
(Reese et al, 1996) or temozolomide (Hickson et al, 1997), encour-
aging clinical trials of such strategies.
It is always difficult to predict clinical outcome from murine
studies and the ultimate test of the value of BG-mediated tumour
sensitization approaches will emerge from ongoing clinical trials.
However, it is hoped that a generation of more tumour-selective
ATase inactivators and anti-tumour agents, perhaps used in
conjunction with gene therapy protection strategies, will define a
more successful approach.
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